BioSpace News Archive

Ongoing Customer-Driven Site Enhancements Designed to Improve User Experience

Distributor will supply Chirascan circular dichroism spectrometers and SX stopped-flow spectrometers to Ireland and Northern Ireland

KB103 is Krystal’s first “off-the-shelf”, topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa.

The Society for Clinical Research Sites (SCRS) announced to almost 1,000 attendees at their 2018 Global Site Solutions Summit that AstraZeneca is the winning sponsor, and Syneos Health (formerly INC Research/inVentiv Health) is the winning CRO of the 2018 SCRS Eagle Award.

Combinations involving checkpoint therapies are starting to be used as the standard of care in certain metastatic cancer types, such as Merck’s Keytruda (pembrolizumab) with chemotherapy in advanced squamous non-small cell lung cancer, according to GlobalData, a leading data and analytics company.

As more and more lawsuits are filed by state and local governments over the opioid epidemic, drugmakers are fighting back in court by demanding the allegations include specifics on how the companies are to blame.

Shares of Clovis Oncology are up more than 7 percent in premarket trading after the company announced positive results from a mid-stage clinical trial that showed patients treated with Rubraca achieved a 44 percent objective response rate in some patients with metastatic castration resistant prostate cancer (mCRPC).

IRRAS AB announced today that, as of October 19, the IRRAS management consists of the following groups and persons:

BL-8040 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer

VIB4920 demonstrated proof-of-concept in a Phase 1b multiple-ascending dose study